Structural, nonclinical, and clinical features of ozoralizumab: A novel tumour necrosis factor inhibitor.
Sign Up to like & getrecommendations! Published in 2023 at "Modern rheumatology"
DOI: 10.1093/mr/road038
Abstract: Tumour necrosis factor (TNF) inhibitors are currently the most widely used biological agents to treat rheumatoid arthritis. Ozoralizumab (OZR), a novel TNF inhibitor, is an antibody using variable heavy-chain domains of heavy-chain antibody (VHHs) and… read more here.
Keywords: necrosis factor; heavy chain; tumour necrosis; nonclinical clinical ... See more keywords